SCNI Stock Overview
A development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Scinai Immunotherapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.35 |
| 52 Week High | US$8.92 |
| 52 Week Low | US$2.23 |
| Beta | 2.36 |
| 1 Month Change | -5.37% |
| 3 Month Change | -6.94% |
| 1 Year Change | -50.96% |
| 3 Year Change | -98.56% |
| 5 Year Change | -99.61% |
| Change since IPO | -99.16% |
Recent News & Updates
Recent updates
Why Scinai Immunotherapeutics' (NASDAQ:SCNI) Healthy Earnings Aren’t As Good As They Seem
Nov 29
Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt
Nov 10Bionvax Pharmaceuticals GAAP EPS of -NIS0.02
Aug 25BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan
Aug 10We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt
Mar 31BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering
Jan 29Shareholder Returns
| SCNI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.9% | -3.8% | -2.7% |
| 1Y | -51.0% | -2.6% | 23.4% |
Return vs Industry: SCNI underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: SCNI underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| SCNI volatility | |
|---|---|
| SCNI Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SCNI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SCNI's weekly volatility has decreased from 18% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 31 | Amir Reichman | www.scinai.com |
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd.
Scinai Immunotherapeutics Ltd. Fundamentals Summary
| SCNI fundamental statistics | |
|---|---|
| Market cap | US$2.90m |
| Earnings (TTM) | US$4.70m |
| Revenue (TTM) | US$452.00k |
0.6x
P/E Ratio6.3x
P/S RatioIs SCNI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCNI income statement (TTM) | |
|---|---|
| Revenue | US$452.00k |
| Cost of Revenue | US$865.00k |
| Gross Profit | -US$413.00k |
| Other Expenses | -US$5.11m |
| Earnings | US$4.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.51 |
| Gross Margin | -91.37% |
| Net Profit Margin | 1,038.94% |
| Debt/Equity Ratio | 2.8% |
How did SCNI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 02:26 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Scinai Immunotherapeutics Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| David Bautz | Zacks Investment Research Inc. |
| David Bautz | Zacks Small-Cap Research |